Anzeige
Meldung des Tages: Milliarden aus Washington? Dieser kritische Rohstoff könnte der nächste Profiteur sein

OKYO PHARMA LTD News

Aktie
WKN:  A2JQ3D ISIN:  GG00BD3FV870 US-Symbol:  EMMLF
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
68,08%
KGV
-
Index-Zuordnung
-

OKYO PHARMA LTD News

30.01.26 - GlobeNewswire
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
28.01.26 - GlobeNewswire
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach
23.01.26 - GlobeNewswire
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
05.01.26 - GlobeNewswire
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer ...
19.12.25 - GlobeNewswire
OKYO Pharma to Ring the Opening Bell at Nasdaq
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company which is developing ...
15.12.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
11.12.25 - GlobeNewswire
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group These ...
03.12.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
21.11.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
18.11.25 - GlobeNewswire
OKYO Pharma to Present at OIS XV in San Diego
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
29.10.25 - GlobeNewswire
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
16.10.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
22.09.25 - GlobeNewswire
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
17.07.25 - GlobeNewswire
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
16.07.25 - GlobeNewswire
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
After 12 weeks of treatment, 75% of per-​protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual ...
11.06.25 - GlobeNewswire
OKYO Pharma to Present at the Bio International Convention
LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
19.05.25 - GlobeNewswire
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
01.05.25 - GlobeNewswire
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-​focused bio-​pharmaceutical company which is ...
30.04.25 - GlobeNewswire
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-​masked, randomized, 12-week placebo-...
31.03.25 - GlobeNewswire
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-​use ampoules for more than 2½ years FDA requires ...

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »